PT  - JOURNAL ARTICLE
AU  - Experton, Bettina
AU  - Tetteh, Hassan A.
AU  - Lurie, Nicole
AU  - Walker, Peter
AU  - Carroll, Colin J.
AU  - Elena, Adrien
AU  - Hein, Christopher S.
AU  - Schwendiman, Blake
AU  - Burrow, Christopher R.
TI  - A Multi-Factor Risk Model for Severe Covid-19, Vaccine Prioritization and Monitoring Based on a 16 Million Medicare Cohort
AID  - 10.1101/2020.10.28.20219816
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.28.20219816
4099  - http://medrxiv.org/content/early/2020/11/17/2020.10.28.20219816.short
4100  - http://medrxiv.org/content/early/2020/11/17/2020.10.28.20219816.full
AB  - Background Public Health interventions to slow the spread of the Covid-19 pandemic focus on protecting individuals at risk for severe disease who will first receive the initially available limited doses of Covid-19 vaccines. Existing risk models for severe Covid-19 and the equitable allocation of vaccines, lack needed integration of both socio-demographic and clinical risk factors.Methods We present an integrated multi-factor risk model for severe Covid-19 combining demographic and clinical data extracted from de-identified Medicare claims for a cohort of 16 million Medicare beneficiaries with over 900,000 Covid-19 cases, and socio-economic data at the county and zip code level from the CDC Social Vulnerability Index. The model based on both logistic regression and random forest and its associated digital maps were developed as part of Project Salus of the Department of Defense Joint Artificial Intelligence Center, for use by military personnel in their supply logistics mission to support the national response to the Covid-19 pandemic.Results The model affirms ethnicity (North American Native: OR 2.01; 95% CI 1.85 - 2.17; Black: OR 1.54; 95% CI 1.51 - 1.57; FI 0.04) as leading factors for hospitalization risk, and age over 85 with the highest association with death (OR 5.73; 95% CI 5.44 - 6.05; FI 0.24). ESRD (OR 2.45; 95% CI 2.35 - 2.56; FI 0.05), prior hospitalization (OR 1.74; 95% CI 1.72 - 1.77; FI 0.15), chronic kidney disease (FI 0.04), morbid obesity (OR 1.57; 95% CI 1.53 - 1.60), pulmonary fibrosis or pulmonary hypertension (OR 1.53; 95% CI 1.49 - 1.57), and CHF (FI 0.04) are leading clinical risk factors for Covid-19 hospitalizations. However, the model reveals low risk for COPD (OR 1.17; 95% CI 1.15 - 1.19), minimal or no risk for diabetes (hospitalization OR 1.02; 95% CI 1.01 - 1.04), and demonstrates an association of preventive behaviors with prior use preventive screenings (OR 0.64; 95% CI 0.62 - 0.66), prior influenza (OR 0.72; 95% CI 0.70 - 0.73) and pneumococcal (OR 0.84; 95% CI 0.81 - 0.87) immunizations with survival.Conclusion This multi-factor risk model concurrently affirmed by different analytical approaches can be applied for use by national and local health authorities for pandemic response, optimizing prioritization of Covid-19 vaccine allocation, and for monitoring vaccine safety and efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Johns Hopkins University Applied Physics Laboratory (JHU-APL) under a prime contract with the Department of Defense Joint Artificial Intelligence Center (JAIC) for Project Salus. Project Salus is a JAIC project in support of the National Guard and other military personnel to provide needed supplies and personnel to health care facilities impacted by the Covid-19 pandemic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was carried out under the supervision of the Department of Defense Joint Intelligence Center under a data use agreement with CMS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Medicare claim data files used in this research is protected health information as defined by the Health Insurance Portability and Accountability Act (HIPAA). Access to these data sets require CMS approval. The 2018 CDC Social Vulnerability Index data can be downloaded from the CDC website. https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html